Beta Drugs Ltd. (BETA) Share Price Falls 8.05% as Small-Cap Stock Turns Top Decliner

Beta Drugs Ltd. Share Price came under pressure on 07 August 2026, with the stock falling to Rs 2,316.10 on NSE, down Rs 202.80 or 8.05% from the previous close of Rs 2,518.90. With a market capitalisation of Rs 2,623.92 crore, the company moved into focus as a small-cap top decliner after the share price decline cleared the exact 8.05% bar tracked for its market-cap category in today’s screen.

For investors following Beta Drugs Ltd. Share Price Today, the move stands out because it was not just a routine intraday fluctuation. The stock opened at Rs 2,539.90, touched a day high of Rs 2,600.00, and then fell to an intraday low of Rs 2,306.00 before trading near that weaker zone around midday. Total traded volume stood at 74,919 shares on NSE, with turnover at Rs 17.35 crore, confirming that the price fall was accompanied by active market participation.

The supplied data confirms the event clearly, but it does not establish a company-specific catalyst behind the decline. That matters for anyone reading Beta Drugs Ltd. Stock News because the verified takeaway today is price action, not an attributed reason. In Univest’s view, the stock is trending because it has entered the top losers list, valuation multiples remain elevated against several industry benchmarks, and the price action has materially undercut the previous close. Investors tracking Beta Drugs Ltd. Share Price should now monitor whether the stock stabilises near the day low, how valuation compares with peers, and whether profitability metrics continue to justify investor attention despite today’s weakness.

Beta Drugs Ltd. (BETA) Share Price Today: Price Action Analysis

Metric	Value
Current Price	Rs 2,316.1
Previous Close	Rs 2,518.9
Today's Change	Rs -202.8 (-8.05%)
Day Open	Rs 2,539.9
Day High	Rs 2,600
Day Low	Rs 2,306
Current Volume (NSE)	74,919
NSE Traded Volume	74,919
Combined NSE + BSE Volume	74,919
Turnover	Rs 17.35 crore
Market Capitalisation	Rs 2,623.92 crore
Market Cap Category	Small Cap

Beta Drugs Ltd. (BETA) traded at Rs 2,316.1. versus the previous close of Rs 2,518.9, a fall of 8.05%. The stock opened at Rs 2,539.9, reached Rs 2,600, touched Rs 2,306. Reported volume was 74,919.

Beta Drugs Ltd. (BETA) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 2,623.92 crore
P/E Ratio	67.31x
P/B Ratio	10.65x
ROE	18.65%
ROCE	22.17%
EPS	Rs 37.42
Dividend Yield	0%

Beta Drugs Ltd. was valued at a P/E ratio of 67.31x, a P/B ratio of 10.65x. These multiples provide valuation context, but they should not be labelled expensive or inexpensive without a comparable peer or sector benchmark.

Profitability and capital efficiency were represented by ROE of 18.65% and ROCE of 22.17%. ROE relates profit to shareholder equity, while ROCE measures returns generated on the capital employed in the business.

Per-share and shareholder-return metrics included EPS of Rs 37.42, dividend yield of 0%. Dividend yield is a current or historical ratio and does not guarantee future distributions.

Beta Drugs Ltd. Fundamental Analysis begins with a mixed but informative setup. The company’s market capitalisation stands at Rs 2,623.92 crore, placing it in the small-cap bracket. Its P/E ratio is 67.31 and its P/B ratio is 10.65, both of which indicate that the market has assigned a relatively rich valuation multiple to the business compared with many listed companies in the same industry. On Beta Drugs Ltd. Share Price metrics alone, that means investors have historically been willing to pay a premium for earnings and net worth, even though the stock is seeing a sharp share price decline today.

Profitability numbers add useful balance. Return on equity is 18.65%, while return on capital employed is 22.17%. Those are healthy operating and capital-efficiency signals in absolute terms, and they help explain why the stock had drawn market interest despite being valued at elevated multiples. EPS is Rs 37.42, which shows the earnings attributable to each share on the supplied basis. Dividend yield is 0, meaning the current or historical payout yield reflected in the data is nil, so the investment case in this stock has not been supported by income distribution.

When viewed together, the figures suggest that Beta Drugs Ltd. is not a low-multiple pharmaceutical stock. Instead, it is a company that combines respectable profitability with a premium valuation. That combination can hold when sentiment is supportive, but it can also attract sharper price action when the market turns cautious and Stocks Falling Today come under the spotlight. In Beta Drugs Ltd. Stock Analysis terms, the key tension is clear: ROE of 18.65% and ROCE of 22.17% support attention, but P/E of 67.31 and P/B of 10.65 leave less room for valuation comfort.

Univest would therefore frame today’s move as a valuation-and-profitability story rather than a purely directional one. Beta Drugs Ltd. Share Price remains tied to whether investors continue to accept premium multiples for the company’s profitability profile within Pharmaceuticals & Drugs. That naturally leads to the sector and benchmark context, where the same ratios can be compared more precisely.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Industry	Pharmaceuticals & Drugs
Benchmark Scope	same industry
Company P/E Ratio	67.31x
Benchmark Median P/E	25.99x
Benchmark Average P/E	81.5x
Benchmark P/E Range	3.3x to 3,493.04x
Company P/B Ratio	10.65x
Benchmark Median P/B	1.86x
Company ROE	18.65%
Benchmark Median ROE	10.59%
Company ROCE	22.17%
Benchmark Median ROCE	12.98%
Company Market Capitalisation	Rs 2,623.92 crore
Benchmark Median Market Cap	Rs 144.63 crore

Beta Drugs Ltd. (BETA) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.

Beta Drugs Ltd. (BETA) has a P/E ratio of 67.31x, which is above the benchmark median of 25.99x, a difference of +158.98%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.

Beta Drugs Ltd. (BETA) has a ROE of 18.65%, which is above the benchmark median of 10.59%, a difference of +76.11%. Beta Drugs Ltd. (BETA) has a ROCE of 22.17%, which is above the benchmark median of 12.98%, a difference of +70.8%.

Track today's top decliners through the Univest top decliners screener. The peer table below provides the company-level comparison.

Beta Drugs Ltd. operates in Healthcare, specifically the Pharmaceuticals & Drugs industry, and the supplied benchmark uses the same industry as its comparison set. Across 137 benchmark companies, the stock stands out for scale and for how its valuation and profitability compare with industry medians and averages.

The company P/E of 67.31 sits far above the industry median P/E of 25.99, although it remains below the industry average P/E of 81.5. The benchmark P/E range is wide, from 3.3 to 3493.04 across 104 companies with available P/E data, showing that pharmaceutical valuations in the listed space can vary dramatically. Even so, Beta Drugs Ltd. Share Price is clearly not priced near the lower end of the industry range. On P/B, the company’s 10.65 is well above the benchmark median of 1.86 and the benchmark average of 2.51, with the industry P/B range running from -16.76 to 16.42 across 136 companies. That places the stock toward the high side of book-value valuation within its peer set.

Profitability tells a more supportive story. Beta Drugs reports ROE of 18.65%, above the benchmark median of 10.59 and the benchmark average of 8.23. ROCE of 22.17% is also above the industry median of 12.98 and the industry average of 15.71. In other words, the company’s returns are stronger than the typical listed peer in the same industry, even though its valuation multiples are also materially higher.

Scale is another factor. The company’s market capitalisation of Rs 2,623.92 crore is well above the benchmark median of Rs 144.63 crore and also above the benchmark average of Rs 500.48 crore, though below the industry maximum of Rs 3,060.41 crore. That positions the company among the larger names in its comparison universe. Univest reads this as an important part of Beta Drugs Ltd. Share Price News Today: the stock is expensive versus typical industry medians, but its profitability and size metrics are also stronger than many peers.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Dishman Carbogen Amcis Ltd.	DCAL	3,060.41	31.3	0.46	-2.89	-0.26
Hikal Ltd.	HIKAL	2,862.43	0	2.29	15.22	16.15
Kwality Pharmaceuticals Ltd.	KPL	2,652.52	40.87	8.32	28.21	26.35
Panacea Biotec Ltd.	PANACEABIO	2,571.92	0	3.06	0	5.36
Solara Active Pharma Sciences Ltd.	SOLARA	2,481.41	0	1.93	17.23	15.34

Beta Drugs Ltd. (BETA) has a P/E ratio of 67.31x compared with the displayed peer median of 0x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 18.65% compares with a peer median of 15.22% across the companies shown in the table. ROCE stood at 22.17% versus the displayed peer median of 15.34%, providing a capital-efficiency comparison. Beta Drugs Ltd. (BETA) has a market capitalisation of Rs 2,623.92 crore. Among the 5 peers shown, 3 have a larger market capitalisation.

Beta Drugs Ltd. Share Price is best understood by comparing its valuation and return profile with nearby listed peers in Pharmaceuticals & Drugs. On market capitalisation, Beta Drugs at Rs 2,623.92 crore sits close to Kwality Pharmaceuticals Ltd. at Rs 2,652.52 crore, above Solara Active Pharma Sciences Ltd. at Rs 2,481.41 crore and Sai Parenteral's Ltd. at Rs 2,290.47 crore, but below Dishman Carbogen Amcis Ltd. at Rs 3,060.41 crore and Hikal Ltd. at Rs 2,862.43 crore.

On P/E, Beta Drugs at 67.31 is higher than Dishman Carbogen Amcis at 31.3, higher than Kwality Pharmaceuticals at 40.87, higher than Fredun Pharmaceuticals at 46.11, and higher than Hester Biosciences at 15.31. It is, however, lower than Sai Parenteral's at 167.74. This indicates the stock trades on a premium multiple against several comparable names, though it is not the most highly valued on earnings in the supplied group.

Its P/B ratio of 10.65 is also above Kwality Pharmaceuticals at 8.32, Fredun Pharmaceuticals at 6.89, Hester Biosciences at 4.58, Solara at 1.93, Panacea Biotec at 3.06 and Hikal at 2.29. Only the broader sector maximum of 16.42 is higher in the benchmark range. That reinforces the point that book-value valuation is demanding.

Profitability is more balanced. Beta Drugs’ ROE of 18.65% is better than Hikal’s 15.22%, Solara’s 17.23%, Fredun’s 11.42%, Sai Parenteral's 13.9%, Panacea Biotec’s 0 and Dishman’s -2.89, but below Kwality Pharmaceuticals at 28.21 and NGL Fine-Chem at 27.9. ROCE of 22.17% is stronger than Hikal’s 16.15%, Solara’s 15.34%, Fredun’s 13.15%, Sai Parenteral's 12.97%, Panacea’s 5.36 and Dishman’s -0.26, while trailing Kwality’s 26.35 and NGL Fine-Chem’s 33.91. Univest therefore sees Beta Drugs as a company with above-average returns, but priced at a premium that remains notable even among nearby peers.

Why Investors Are Watching Beta Drugs Ltd.

Beta Drugs Ltd. is on investor screens because today’s move combined a clear price fall with meaningful turnover and a valuation profile that already sat above several industry benchmarks. In a session where Stocks in News and Market Movers are being filtered for outsized moves, this stock stands out as a small-cap pharmaceutical name whose decline has been large enough to trigger broader tracking across NSE News and BSE News searches, even though the reported trading volume in the supplied data is on NSE.

• Price action: the stock fell 8.05% to Rs 2,316.10 from the previous close of Rs 2,518.90 after trading between Rs 2,600.00 and Rs 2,306.00.
• Turnover and participation: 74,919 shares were traded on NSE, generating Rs 17.35 crore in turnover.
• Fundamental context: P/E of 67.31 and P/B of 10.65 are elevated, while ROE of 18.65% and ROCE of 22.17% remain comparatively strong.
• Sector position: the company operates in Healthcare within Pharmaceuticals & Drugs and is larger than the industry median by market capitalisation.
• Relative valuation: compared with several peers, the stock trades at a premium on both earnings and book value metrics.

What investors should monitor next is not a prediction about direction but whether the stock continues to trade near the session low, how the market responds to a premium valuation after a sharp decline, and whether Beta Drugs Ltd. Share Price begins to stabilise relative to peer and sector metrics. Univest also notes that the verified data establishes the move, but not a company-specific catalyst.

About Beta Drugs Ltd.

Beta Drugs Ltd. is a listed company in the Healthcare sector and the Pharmaceuticals & Drugs industry. That places it within one of the more widely tracked segments of the Indian stock market, where investors regularly compare valuation, profitability and market-cap scale across a broad listed universe. In the supplied industry benchmark, Beta Drugs is part of a 137-company same-industry comparison set, which helps frame its standing more precisely than a generic market view.

Based on the verified data, the company’s listed-market position is that of a small-cap pharmaceutical business with a market capitalisation of Rs 2,623.92 crore. Within its industry set, that market value is materially above the median of Rs 144.63 crore and the average of Rs 500.48 crore, showing that it sits among the bigger listed names in this comparison pool. That scale gives Beta Drugs Ltd. Share Price added visibility when it appears in Top Losers Today or broader Share Market Today screens.

The financial profile available in the data suggests a company that has delivered stronger profitability than many peers, with ROE of 18.65% and ROCE of 22.17%, but which also trades at premium valuation multiples, including a P/E of 67.31 and P/B of 10.65. For readers looking at Beta Drugs Ltd. Latest News and Beta Drugs Ltd. Company News, that combination is central: the stock’s market relevance comes from both its relatively strong returns and its expensive positioning within Pharmaceuticals & Drugs.

Track Beta Drugs Ltd. Share Price on Univest

Use Beta Drugs Ltd. (BETA) live share-price page, Univest top decliners screener, Univest market blogs to review live stock data, top decliners lists and related market analysis.

Readers who want to follow Beta Drugs Ltd. Share Price more closely can use Univest to track live share price moves, market capitalisation, valuation ratios, profitability indicators and broader stock performance context. Univest also helps users review 52-week levels, compare sector and peer data, and monitor how names in Healthcare and Pharmaceuticals & Drugs are moving across market sessions.

For investors scanning Beta Drugs Ltd. Share Price Live, Beta Drugs Ltd. Share Price Update or Beta Drugs Ltd. NSE activity, a structured dashboard matters because a single-session decline often needs to be viewed alongside P/E, P/B, ROE, ROCE, EPS and relative industry positioning. Univest brings those metrics into one place so users can track price action and financial context together rather than in isolation.

Frequently Asked Questions

Why is Beta Drugs Ltd. Share Price falling today?

Ans. Beta Drugs Ltd. Share Price fell 8.05% to Rs 2,316.10 from the previous close of Rs 2,518.90. The supplied data confirms the decline and active trading turnover of Rs 17.35 crore, but it does not identify a company-specific catalyst.

What is Beta Drugs Ltd. Share Price Today on NSE?

Ans. Beta Drugs Ltd. Share Price Today is Rs 2,316.10 on NSE. The stock opened at Rs 2,539.90, touched a day high of Rs 2,600.00 and a day low of Rs 2,306.00, showing a wide intraday range.

How much did Beta Drugs Ltd. stock decline in today’s session?

Ans. The stock declined by Rs 202.80 in absolute terms and by 8.05% in percentage terms. That move placed Beta Drugs Ltd. among the top decliners in the tracked screen for the day’s market decline.

What is the market capitalisation of Beta Drugs Ltd.?

Ans. Beta Drugs Ltd. has a market capitalisation of Rs 2,623.92 crore. In the supplied classification, that places it in the Small Cap category, which is why today’s 8.05% price fall attracted additional attention.

How active was trading in Beta Drugs Ltd. shares today?

Ans. Trading activity reached 74,919 shares on NSE, which also matched total reported volume in the supplied data. Turnover came in at Rs 17.35 crore, indicating that the share price decline was accompanied by meaningful value participation.

Is Beta Drugs Ltd. expensive compared with its industry benchmark?

Ans. On supplied sector data, the company P/E is 67.31 versus the industry median of 25.99, while P/B is 10.65 versus the industry median of 1.86. That places valuation above typical benchmark levels in Pharmaceuticals & Drugs.

How profitable is Beta Drugs Ltd. based on available ratios?

Ans. Beta Drugs reports ROE of 18.65% and ROCE of 22.17%, both above the industry median figures of 10.59 and 12.98 respectively. That suggests stronger profitability than many same-industry companies in the supplied comparison universe.

What is the EPS and dividend yield of Beta Drugs Ltd.?

Ans. The supplied EPS is Rs 37.42, which reflects earnings attributable to each share. Dividend yield is 0, indicating the current or historical payout yield captured in the data is nil relative to the stock price.

How does Beta Drugs Ltd. compare with peers on valuation?

Ans. Beta Drugs trades at a P/E of 67.31, higher than Dishman Carbogen Amcis at 31.3, Kwality Pharmaceuticals at 40.87 and Hester Biosciences at 15.31, but below Sai Parenteral's at 167.74 in the supplied peer set.

Which sector and industry does Beta Drugs Ltd. belong to?

Ans. Beta Drugs Ltd. belongs to the Healthcare sector and the Pharmaceuticals & Drugs industry. The supplied benchmark covers 137 same-industry companies, providing the context used for valuation, profitability and market-cap comparison in this article.